EANS-News: Intercell and Boehringer Ingelheim Vetmedica GmbH enter into strategic partnership to develop animal vaccines

-
» Worldwide agreement for the use of certain Intercell's
AIP®-derived
antigens to develop and commercialize animal
vaccines
» Intercell to receive upfront, option and milestone
payments as well as
royalties on product net sales

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

Subtitle: - » Worldwide agreement for the use of certain Intercell's
AIP®-derived antigens to develop and commercialize animal vaccines
» Intercell to receive upfront, option and milestone payments as well
as royalties on product net sales

Vienna (Austria), May 10, 2010 (euro adhoc) - Intercell AG (VSE:
ICLL) today announced that it has entered into a worldwide Option and
Exclusive License Agreement under which Boehringer Ingelheim
Vetmedica has the right to use certain antigens derived from
Intercell´s Antigen Identification Program (AIP®) to develop animal
vaccines. Under the agreement, Intercell will receive upfront, option
and milestone payments as well as royalties on product net sales.

"Having partnered a number of our vaccine candidates derived from our
AIP® with leading human vaccine players such as Merck and Novartis,
we are very pleased to leverage the value of this successful
technology also with a major animal vaccine company like Boehringer
Ingelheim Vertmedica. This will allow us to further potentiate the
technology and explore its technological and economical power beyond
the area of human health", stated Gerd Zettlmeissl, CEO of Intercell.

"We are pleased to partner with Intercell and to gain access to
attractive vaccine targets generated by AIP®. We are committed to
develop innovative vaccines to meet the urgent needs for the benefit
of animal health," stated Joachim Hasenmaier, CEO of Boehringer
Ingelheim Vetmedica.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Vice President, Global Head Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market